Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +42

Arrowstreet Capital Limited Partnership Sells 99,210 Shares of Charles ...

AI-generated analysis

📉 Arrowstreet Capital Limited Partnership decreased its holdings in Charles River Laboratories International by 11.9% during the first quarter.

💰 The remaining institutional stake held by Arrowstreet is valued at $127,138,000 as of the latest SEC filing.

📈 Several other institutions including Tema Etfs LLC and Los Angeles Capital Management LLC purchased new stakes in the fourth quarter.

📉 CLSA downgraded CRL from 'outperform' to 'hold' with a price target of $219.00 on July 20th.

📉 JPMorgan Chase dropped its price target from $165.00 to $160.00 and assigned a neutral rating in April.

📈 Barclays raised its price objective to $220.00 and maintained an 'overweight' rating in May.

📈 Sanford C. Bernstein set a high price objective of $250.00 with a Buy rating in July.

📊 The stock currently holds a consensus rating of 'Moderate Buy' with an average analyst price target of $220.75.

💰 Director James C. Foster sold 75,000 shares for $16.875 million under a Rule 10b5-1 trading plan on June 29th.

📈 The company reported EPS of $2.06 in the quarter ended May 7th, beating analyst estimates of $1.96.

💵 Revenue for the quarter reached $995.83 million, surpassing expectations of $977.46 million.

📅 Charles River Laboratories set FY 2026 EPS guidance between $10.80 and $11.30.

Bullish Signals
  • Charles River Laboratories beat quarterly earnings estimates with reported EPS of $2.06 versus the consensus of $1.96.
  • The company exceeded revenue expectations, reporting $995.83 million against analyst forecasts of $977.46 million.
  • Barclays raised its price target to $220 and assigned an 'overweight' rating, indicating strong institutional confidence.
  • Sanford C. Bernstein set a high price objective of $250, reflecting bullish sentiment from major equity research firms.
  • The stock maintains a consensus 'Moderate Buy' rating with an average analyst price target of $220.75.
Risk Factors
  • CLSA downgraded the stock to a 'hold' rating and lowered its price target to $219, signaling caution.
  • JPMorgan Chase reduced its price target to $160 and assigned a neutral rating, suggesting limited upside potential.
  • Director James C. Foster executed a significant sale of 75,000 shares, reducing his position by over 70%.
Full Analysis
Arrowstreet Capital Limited Partnership reduced its stake in Charles River Laboratories International (NYSE:CRL) by 11.9% during the first quarter, selling 99,210 shares to hold a remaining position of 737,030 shares valued at approximately $127.1 million. While Arrowstreet decreased its holdings, several other institutional investors increased their positions in the fourth quarter, including Tema Etfs LLC, Los Angeles Capital Management LLC, and Sfam LLC, with Activest Wealth Management showing a significant percentage increase in its small stake. Analyst sentiment regarding CRL remains mixed but generally positive. CLSA downgraded the stock to a 'hold' rating with a $219 price target, while JPMorgan Chase lowered its target to $160 with a neutral rating. Conversely, Barclays raised its objective to $220 with an 'overweight' rating, and Sanford C. Bernstein set a high target of $250. The consensus rating is currently a 'Moderate Buy' with an average price target of $220.75. Financially, Charles River Laboratories reported strong quarterly results in May, beating earnings per share estimates of $1.96 with actual EPS of $2.06 and revenue of $995.83 million, which exceeded expectations of $977.46 million. The company provided full-year 2026 guidance ranging between $10.80 and $11.30 per share, slightly below the average analyst expectation of $11.05. Additionally, Director James C. Foster sold a significant portion of his holdings via a pre-arranged trading plan.